Abstract
During neurogenesis, precursor cells undergo a defined number of divisions and terminally differentiate as postmitotic neurons. In the adult mammal, under certain conditions, postmitotic neurons re-enter the cell cycle and divide. The accumulated evidence demonstrates that the precise control of cell-cycle progression is critical for both neuronal development and maintenance of the neuronal phenotype. Cyclin-dependent Kinase Inhibitors (CDKIs) play the key role in this neuronal differentiation process of coordinating cell cycle exit and differentiation. Importantly, deregulation of the cell cycle leads to a variety of human neuronal diseases. In this review we discuss how regulation of neuronal progenitor proliferation and neuronal differentiation are coupled processes, based on evidence derived from the study of multiple animal models (mouse, Drosophila and Xenopus). In addition, we discuss the involvement of CDKIs in human neuronal diseases including cancers of neuronal systems, Alzheimer ’ s disease, and psychological disorders, and their potential as pharmacological targets.
Keywords: Cell cycle, G1/S phase, cyclin dependent kinase inhibitor, neuronal differentiation
Central Nervous System Agents in Medicinal Chemistry
Title: Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Volume: 7 Issue: 2
Author(s): Maryline Paris and Ourania M. Andrisani
Affiliation:
Keywords: Cell cycle, G1/S phase, cyclin dependent kinase inhibitor, neuronal differentiation
Abstract: During neurogenesis, precursor cells undergo a defined number of divisions and terminally differentiate as postmitotic neurons. In the adult mammal, under certain conditions, postmitotic neurons re-enter the cell cycle and divide. The accumulated evidence demonstrates that the precise control of cell-cycle progression is critical for both neuronal development and maintenance of the neuronal phenotype. Cyclin-dependent Kinase Inhibitors (CDKIs) play the key role in this neuronal differentiation process of coordinating cell cycle exit and differentiation. Importantly, deregulation of the cell cycle leads to a variety of human neuronal diseases. In this review we discuss how regulation of neuronal progenitor proliferation and neuronal differentiation are coupled processes, based on evidence derived from the study of multiple animal models (mouse, Drosophila and Xenopus). In addition, we discuss the involvement of CDKIs in human neuronal diseases including cancers of neuronal systems, Alzheimer ’ s disease, and psychological disorders, and their potential as pharmacological targets.
Export Options
About this article
Cite this article as:
Paris Maryline and Andrisani M. Ourania, Regulators of the G1 Phase of the Cell Cycle and Neurogenesis, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/187152407780831675
DOI https://dx.doi.org/10.2174/187152407780831675 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Blockade of Ser16-Hsp20 Phosphorylation Attenuates Neuroprotection Dependent Upon Bcl-2 and Bax
Current Neurovascular Research Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Inhibition of Brain Ischemia-Caused Notch Activation in Microglia May Contribute to Isoflurane Postconditioning-Induced Neuroprotection in Male Rats
CNS & Neurological Disorders - Drug Targets A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry The Role of the Osteoimmune Axis in the Inflammation of the Inner Auditory Ear and with Regard to the Putative Anticarcinogenetic Principle: Part 2
Inflammation & Allergy - Drug Targets (Discontinued) Multidrug Transporters as Drug Targets
Current Drug Targets Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Compounds Combining Aminoadamantane and Monoterpene Moieties: Cytotoxicity and Mutagenic Effects
Medicinal Chemistry The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry